Pfizer buys Amplyx Pharmaceuticals from Lundbeckfonden

Amplyx CEO Ciara Kennedy sees Pfizer as the ideal home for Amplyx Pharmaceuticals' therapeutic candidates which focus on treating illnesses and helping people with compromised immune systems.

Photo: Matthew Childs/REUTERS / X03810

Lundbeckfonden Ventures is selling portfolio company Amplyx Pharmaceuticals to Pfizer, according to a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs